US20010023251A1 - Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions - Google Patents

Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions Download PDF

Info

Publication number
US20010023251A1
US20010023251A1 US09/815,995 US81599501A US2001023251A1 US 20010023251 A1 US20010023251 A1 US 20010023251A1 US 81599501 A US81599501 A US 81599501A US 2001023251 A1 US2001023251 A1 US 2001023251A1
Authority
US
United States
Prior art keywords
preparing
drug
compounds according
compounds
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/815,995
Other versions
US6444706B2 (en
Inventor
Eberhard Amtmann
Norbert Frank
Gerhard Sauer
Gerhard Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioSphings AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/815,995 priority Critical patent/US6444706B2/en
Publication of US20010023251A1 publication Critical patent/US20010023251A1/en
Application granted granted Critical
Publication of US6444706B2 publication Critical patent/US6444706B2/en
Assigned to BIOSPHINGS AG reassignment BIOSPHINGS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CANCER RESEARCH VENTURES LIMITED
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to new guanidine derivatives, processes for preparing them and their use as sphingomyelinase inhibitors and pharmaceutical compositions which contain these compounds.
  • X denotes R 1 , —NHR 1 , —NH—NH—CHR 1 R 2 , —NH—N ⁇ CR 1 R 2 ,
  • R 1 and R 2 independently of each other denote hydrogen, a straight-chained or branched C 3-20 -alkyl, C 3-20 -cycloalkyl group, an adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, indolyl, quinolyl, anthracenyl, phenanthryl, perinaphthyl or quinuclidinyl group, wherein the above-mentioned straight-chained or branched C 3-20 -alkyl group may be substituted by a hydroxy or C 1-4 -alkoxy group, a halogen atom or an amino group and the above-mentioned C 3-20 -cycloalkyl group may be substituted by a hydroxy, C 1-4 -alkoxy, C 1-4 -alkyl group or by a halogen atom or an amino group, and wherein, if X denote hydrogen,
  • Preferred compounds of general formula I are those wherein
  • X denotes —NH—NH—CH 2 R 1 and —NH—N ⁇ CHR 1
  • R 1 denotes C 8-20 -alkyl (branched or unbranched).
  • X denotes —NH—NH—CH 2 R 1 and —NH—N ⁇ CHR 1 and
  • R 1 denotes an unbranched decyl group.
  • the compounds according to the invention have valuable pharmacodynamic and biochemical properties and can therefore be used advantageously in research and in human and veterinary medicine.
  • aminoguanidines and amidines according to the invention have beneficial sphingomyelinase-inhibiting, antimicrobial, antiviral, anti-inflammatory (e.g. anti-shock) activities and effects on cell growth.
  • the compounds according to the invention are prepared by reacting an aldehyde or ketone of formula R 1 CHO or R 1 COR 2 with aminoguanidine.
  • the reaction is usually carried out in an inert organic solvent, e.g. a chlorinated hydrocarbon, such as dichloromethane or chloroform, or an aromatic hydrocarbon such as benzene or toluene.
  • the reaction is preferably carried out by removing the water formed from the equilibrium, e.g. using a water separator.
  • the reaction may be carried out over a wide temperature range but is generally performed at elevated temperature, particularly at a temperature in the range from about 60° C. up to the boiling point of the reaction mixture.
  • the compounds according to the invention may be prepared by methods known from the prior art.
  • the starting compounds are known or may be prepared by known methods.
  • compositions according to the invention contain one of the above-mentioned compounds of general formula I in a conventional solid or liquid pharmaceutical carrier.
  • the compounds according to the invention may also be combined with known active substances.
  • the compounds according to the invention are characterised by anti-inflammatory (e.g. anti-shock), antimicrobial, antitumoral and, in particular, antiviral effects.
  • the antiviral spectrum of activity includes, for example, herpes, vesicular stomatitis, HIV and papilloma viruses. It has also been found that the compounds according to the invention influence the growth of tumour cells. They may be used to treat carcinomas, e.g. carcinoma of the large intestine, sarcomas or leukaemias.
  • ARDS adult respiratory distress syndrome
  • tumour therapy in combination with chemotherapy, radiotherapy and cytokine treatment such as TNF- ⁇ treatment of sarcomas, carcinomas and leukaemias
  • the compounds according to the invention may be administered by parental, subcutaneous, intravenous, intramuscular and intraperitoneal route.
  • the carrier substance is a sterile liquid such as water or oil, the oil being of vegetable, animal or synthetic origin. Conventional glucose solutions are used as the injectable solutions.
  • the liquid carriers for the injectable solutions generally contain 0.5 to 26% by weight of active substance.
  • the compounds according to the invention may be administered orally with equal success.
  • the compounds are also suitable for treating pneumonia and are administered in the form of a vapour or spray to the oral and nasal cavity.
  • compositions in the form of tablets, capsules, powders, solutions, suspensions or elixirs are particularly preferred.
  • the quantity of active ingredient in these preparations is at least 1% by weight, based on the total weight of the composition.
  • the active substances according to the invention may also be administered topically, e.g. in ointments, creams, emulsions or lotions.
  • composition Active substance according to the 20 parts by weight invention Stearic acid 6 parts by weight Glucose 474 parts by weight
  • the ingredients are processed in the usual way to form tablets weighing 500 mg. If desired, the content of active substance may be increased or reduced and the quantity of glucose reduced or increased accordingly.
  • Composition Active substance according to the 100 parts by weight invention Powdered lactose 45 parts by weight Cocoa butter 1555 parts by weight
  • Micronised powdered active substance (compound of formula I; particle size about 0.5 to 7 ⁇ m) is packed into hard gelatine capsules in a quantity of 5 mg, optionally with the addition of micronised lactose.
  • the powder is inhaled from conventional inhalers, e.g. according to DE-A 33 45 722, to which reference is hereby made.
  • the precipitate is dissolved in ethyl acetate and mixed with petroleum ether at boiling temperature (boiling range 40 to 60° C.) until beginning to turn cloudy. Fine crystals are obtained, m.p. 101° C. The structure and purity of the compound were confirmed by analytical and spectroscopic data.
  • the virostatic properties were determined by in vitro tests. The following virus strains were used:
  • Cell cultures (monkey kidney cells or human fibroblasts) are infected with herpes and a series of cultures are exposed to medium containing various concentrations of the test substance. After 24 hours the concentration of the virus descendants in the cell culture supernatant is determined by plaque assays. The concentration of substance at which the virus replication is inhibited by 50% (IC 50 ) is determined from dosage/activity curves.
  • FIG. 1 Protection from endotoxic shock by C11AG is illustrated by FIG. 1:
  • mice (strain NMRI/Nu, 8 weeks old, female) were each given 0.2 mg of endotoxin from E. coli (Sigma, Kunststoff) by intraperitoneal route. The 10 control animals, who had been given 0.2 ml of 5% glucose subcutaneously, died within 24 hours. Nine animals were injected subcutaneously with 50 mg/kg of C11AG 30 minutes before the endotoxin treatment. Of this group, only 2 animals died.
  • An autoimmune reaction against cartilagenous tissue was produced by injecting collagen into DBA/I mice as described (Holmdahl, R. et al., Immunology, 65, 305-310, 1988). Groups of 10 animals were used as control or were given 50 mg/kg or 100 mg/kg of C11AG per day by oral route. The drug was administered in the food (Altromin, powdered food) and the dosage was calculated from the daily food intake. The symptoms were evaluated daily for each individual paw from 0.5-3 as described [R. Holmdahl, et al., Immunology, 65, 305-310, (1988)]. The total symptoms of every animal in each group—on day 7 after the booster injection—are shown in the following Table: Treatment Total Symptoms Control 0 Collagen 35 Collagen/50 mg/kg C11AG 4.5 Collagen/100 mg/kg C11AG 1
  • 14 C sphingomyelin (10 ⁇ g/ml) was incubated with neutral SMase (membrane fraction isolated from mice brains, 10 ⁇ g of protein/mixture [according to S. Gatt, Biochem. Biophys. Res. Commun. 68, 235-241 (1976)] in the presence of various concentrations of the test substances (for 2 hours at 37° C. 20 mM Tris, 1 mM MgCl 2 .pH 7.5). Then the samples were extracted with 5 times the volume of chloroform/methanol (1:1) and the content of radioactive phosphorylcholine in the aqueous phase was determined. The IC 50 was obtained from dosage/activity curves.
  • neutral SMase membrane fraction isolated from mice brains, 10 ⁇ g of protein/mixture [according to S. Gatt, Biochem. Biophys. Res. Commun. 68, 235-241 (1976)] in the presence of various concentrations of the test substances (for 2 hours
  • 14 C sphingomyelin (10 ⁇ g/ml) were incubated with neutral SMase (membrane fraction isolated from mouse brains, 10 ⁇ g protein/mixture, according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976) or with acidic SMase (microsome fraction from macrophage 5 ⁇ g of protein/mixture isolated according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976) in the presence of various concentrations of the test substances, for 2 hours at 37° C.
  • neutral SMase membrane fraction isolated from mouse brains, 10 ⁇ g protein/mixture, according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976
  • acidic SMase microsome fraction from macrophage 5 ⁇ g of protein/mixture isolated according to Gatt, S. Biochem. Biophys. Res
  • FIG. 4 shows, by a simple logarithmic representation, the sphingomyelinase inhibition for neutral and acidic sphingomyelinase [in %] as a function of the C11AG concentration [ ⁇ g/ml].
  • FIG. 5 graphically shows the average tumour size as a function of the duration of treatment for various doses of C11AG.
  • Curve A shows the tumour growth of the control animals.
  • Curve B shows the pattern of size for a dosage of 50 mg/kg C11AG and curve C shows the corresponding pattern for 100 mg/kg C11AG.
  • FIG. 6 shows, by a simple logarithmic representation, the sphingomyelinase inhibition for neutral—curve A—and acidic sphingomyelinase [in %]—curve B—as a function of the H 2 C11AG concentration [ ⁇ g/ml].
  • mice of the Balb C strain (about 8 weeks old) were given 0.7 mg of endotoxin from E. coli (in 0.2 ml of isotonic saline solution) by intraperitoneal injection.
  • 10 animals were given 100 mg/kg of H 2 C11AG (dissolved in twice distilled water) by oesphageal tube 2 hours before the LPS treatment.
  • the control animals were given water. The surviving animals were observed for 12 days.
  • FIG. 7 shows the survival rate of untreated experimental animals (A) compared with those who were treated with a dose of 100 mg H 2 C11AG, as described above.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention concerns new guanidine derivatives of formula (I), methods of preparing them and their use in drugs containing such compounds.
Figure US20010023251A1-20010920-C00001

Description

  • The present invention relates to new guanidine derivatives, processes for preparing them and their use as sphingomyelinase inhibitors and pharmaceutical compositions which contain these compounds. [0001]
  • The guanidine derivatives of the present invention correspond to the general formula I: [0002]
    Figure US20010023251A1-20010920-C00002
  • wherein [0003]
  • X denotes R[0004] 1, —NHR1, —NH—NH—CHR1R2, —NH—N═CR1R2,
    Figure US20010023251A1-20010920-C00003
  • R[0005] 1 and R2 independently of each other denote hydrogen, a straight-chained or branched C3-20-alkyl, C3-20-cycloalkyl group, an adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, indolyl, quinolyl, anthracenyl, phenanthryl, perinaphthyl or quinuclidinyl group, wherein the above-mentioned straight-chained or branched C3-20-alkyl group may be substituted by a hydroxy or C1-4-alkoxy group, a halogen atom or an amino group and the above-mentioned C3-20-cycloalkyl group may be substituted by a hydroxy, C1-4-alkoxy, C1-4-alkyl group or by a halogen atom or an amino group, and wherein, if X denotes —NH—N═CRR2, only one of the substituents R1 and R2 may represent hydrogen
  • optionally in the form of individual optical isomers, mixtures of the individual isomers or racemates, tautomers or geometrical isomers e.g. cis/trans-isomers as well as in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids. [0006]
  • Preferred compounds of general formula I are those wherein [0007]
  • X denotes —NH—NH—CH[0008] 2R1 and —NH—N═CHR1
  • R[0009] 1 denotes C8-20-alkyl (branched or unbranched).
  • Particularly preferred compounds of general formula I are those wherein [0010]
  • X denotes —NH—NH—CH[0011] 2R1 and —NH—N═CHR1 and
  • R[0012] 1 denotes an unbranched decyl group.
  • The compounds according to the invention have valuable pharmacodynamic and biochemical properties and can therefore be used advantageously in research and in human and veterinary medicine. [0013]
  • Surprisingly it has been found that the aminoguanidines and amidines according to the invention have beneficial sphingomyelinase-inhibiting, antimicrobial, antiviral, anti-inflammatory (e.g. anti-shock) activities and effects on cell growth. [0014]
  • The compounds according to the invention are prepared by reacting an aldehyde or ketone of formula R[0015] 1CHO or R1COR2 with aminoguanidine. The reaction is usually carried out in an inert organic solvent, e.g. a chlorinated hydrocarbon, such as dichloromethane or chloroform, or an aromatic hydrocarbon such as benzene or toluene. The reaction is preferably carried out by removing the water formed from the equilibrium, e.g. using a water separator. The reaction may be carried out over a wide temperature range but is generally performed at elevated temperature, particularly at a temperature in the range from about 60° C. up to the boiling point of the reaction mixture. In addition, the compounds according to the invention may be prepared by methods known from the prior art.
  • The starting compounds are known or may be prepared by known methods. [0016]
  • The pharmaceutical compositions according to the invention contain one of the above-mentioned compounds of general formula I in a conventional solid or liquid pharmaceutical carrier. The compounds according to the invention may also be combined with known active substances. [0017]
  • The compounds according to the invention are characterised by anti-inflammatory (e.g. anti-shock), antimicrobial, antitumoral and, in particular, antiviral effects. The antiviral spectrum of activity includes, for example, herpes, vesicular stomatitis, HIV and papilloma viruses. It has also been found that the compounds according to the invention influence the growth of tumour cells. They may be used to treat carcinomas, e.g. carcinoma of the large intestine, sarcomas or leukaemias. [0018]
  • In general, it is found that these substances according to the invention bring about an NF-kappaB-dependent immunosuppression. [0019]
  • The compounds according to the invention can therefore be used to treat the following diseases: [0020]
  • A. Systemic inflammatory reactions [0021]
  • sepsis-causing diseases [0022]
  • gram-positive sepsis [0023]
  • gram-negative sepsis [0024]
  • fungal sepsis [0025]
  • agranulocytosis (neutropenic fever) [0026]
  • urinary infections (urosepsis) [0027]
  • general infections with meningococci (meningococcaemia) [0028]
  • trauma/haemorrhage [0029]
  • burns [0030]
  • injuries caused by ionising radiation [0031]
  • acute pancreatitis [0032]
  • adult respiratory distress syndrome (ARDS) [0033]
  • B. Reperfusion syndrome [0034]
  • post pump syndrome [0035]
  • ischaemia-induced reperfusion injury [0036]
  • C. Cardiovascular disease: [0037]
  • cardiac stun syndrome [0038]
  • myocardial infarction [0039]
  • congestive heart failure [0040]
  • arteriosclerosis [0041]
  • D. Infectious diseases: [0042]
  • papilloma virus infection [0043]
  • herpes virus infection [0044]
  • HIV infection/HIV neuropathy [0045]
  • meningitis [0046]
  • hepatitis [0047]
  • septic arthritis [0048]
  • peritonitis [0049]
  • pneumonia [0050]
  • bronchitis [0051]
  • epiglottitis [0052]
  • [0053] E. coli 0157:H7 infection
  • haemolytic uremic syndrome/thrombolytic thromocytopenic purpura [0054]
  • malaria [0055]
  • Dengue haemorrhagic fever [0056]
  • Leishmaniasis [0057]
  • leprosy [0058]
  • toxic shock syndrome [0059]
  • [0060] Streptococcal myositis
  • gas gangrene [0061]
  • myobacterium tuberculosis infections [0062]
  • myobacterium avium intracellular infections [0063]
  • pneumocystosis [0064]
  • pelvic inflammatory disease [0065]
  • orchitis/epidydimitis [0066]
  • Legionella [0067]
  • lyme disease [0068]
  • influenza A virus infection [0069]
  • diseases caused by Epstein-Barr virus [0070]
  • viral-associated haemaphagocytic syndrome [0071]
  • viral encephalitis/aseptic meningitis [0072]
  • E. Gynaecological applications [0073]
  • premature labour [0074]
  • miscarriage [0075]
  • infertility [0076]
  • F. Inflammatory diseases/autoimmune diseases: [0077]
  • rheumatoid arthritis/seronegative arthropathy [0078]
  • emphysema bronchitis (chronic obstructive pulmonary disease COPD) [0079]
  • osteoarthritis [0080]
  • inflammatory bowel disease [0081]
  • Crohn's disease [0082]
  • systemic lupus erythematosis [0083]
  • iridocyclitis/uveitis/optic neuritis [0084]
  • idiopathic pulmonary fibrosis [0085]
  • systemic vasculitis/Wegner's granulomatosis [0086]
  • sarcoidosis [0087]
  • orchitis/vasectomy reversal procedures [0088]
  • H. Allergic/atopic diseases: [0089]
  • asthma [0090]
  • allergic rhinitis [0091]
  • eczema [0092]
  • allergic contact dermatitis [0093]
  • allergic conjunctivitis [0094]
  • hypersensitive pneumonitis [0095]
  • I. Malignant disease: [0096]
  • tumour therapy in combination with chemotherapy, radiotherapy and cytokine treatment such as TNF-α treatment of sarcomas, carcinomas and leukaemias [0097]
  • ALL [0098]
  • AML [0099]
  • CML [0100]
  • CLL [0101]
  • breast cancer [0102]
  • small-cell and non-small-cell bronchial carcinoma [0103]
  • squamous cell carcinoma [0104]
  • Hodgkin's disease, non-Hodgkin's lymphoma [0105]
  • multiple melanoma [0106]
  • Kaposi's sarcoma [0107]
  • colorectal carcinoma [0108]
  • nasopharyneal carcinoma [0109]
  • malignant histiocytosis [0110]
  • paraneoplastic syndrome/hypercalcaemia of malignancy [0111]
  • J. Transplant complications [0112]
  • rejection reactions after transplant [0113]
  • graft versus host reactions [0114]
  • K. Cachexia [0115]
  • L. Congenital diseases: [0116]
  • cystic fibrosis [0117]
  • familial hematophagocytic lymphohistiocytosis [0118]
  • sickle cell anaemia [0119]
  • M. Skin diseases: [0120]
  • psoriasis [0121]
  • alopecia [0122]
  • N. Neurological diseases/chronic and acute neurodegeneration [0123]
  • multiple sclerosis [0124]
  • Parkinson's disease [0125]
  • Down's syndrome [0126]
  • stroke [0127]
  • skull/brain trauma [0128]
  • migraine [0129]
  • O. Diseases of the kidneys: [0130]
  • nephrotic syndrome [0131]
  • haemodialysis [0132]
  • uraemia [0133]
  • P. Various toxicities: [0134]
  • OKT3 therapy [0135]
  • anti-CD3 therapy [0136]
  • cytokine therapy [0137]
  • chemotherapy [0138]
  • radiation therapy [0139]
  • chronic salicylate intoxication [0140]
  • Q. Metabolic/idiopathic diseases: [0141]
  • Wilson's disease [0142]
  • haemachromatosis [0143]
  • alpha-1-antitrypsin deficiency [0144]
  • diabetes [0145]
  • Hashimoto's thyroiditis [0146]
  • osteoporosis [0147]
  • hypothalamic pituitary adrenal axis evaluation [0148]
  • primary biliary cirrhosis [0149]
  • In vitro investigations in plaque reduction tests using different viruses showed an inhibition of growth at substance concentrations of from 0.1 to 1000/μg/ml. The toxicity of the substances according to the invention is relatively low. They may be used in particular as effective preventative or therapeutic agents against influenza, AIDS or herpes diseases of the skin and mucous membranes. The daily dose for adults during the disease is of the order of about 5 to 1000 mg of active substance per day. [0150]
  • The compounds according to the invention may be administered by parental, subcutaneous, intravenous, intramuscular and intraperitoneal route. In this case, the carrier substance is a sterile liquid such as water or oil, the oil being of vegetable, animal or synthetic origin. Conventional glucose solutions are used as the injectable solutions. The liquid carriers for the injectable solutions generally contain 0.5 to 26% by weight of active substance. The compounds according to the invention may be administered orally with equal success. The compounds are also suitable for treating pneumonia and are administered in the form of a vapour or spray to the oral and nasal cavity. For oral administration, compositions in the form of tablets, capsules, powders, solutions, suspensions or elixirs are particularly preferred. The quantity of active ingredient in these preparations is at least 1% by weight, based on the total weight of the composition. The active substances according to the invention may also be administered topically, e.g. in ointments, creams, emulsions or lotions. [0151]
  • The Examples which follow show some possible formulations for the preparations:[0152]
    • FORMULATION EXAMPLES
  • 1. Tablets [0153]
  • Composition: [0154]
    Active substance according to the 20 parts by weight
    invention
    Stearic acid
    6 parts by weight
    Glucose 474 parts by weight
  • The ingredients are processed in the usual way to form tablets weighing 500 mg. If desired, the content of active substance may be increased or reduced and the quantity of glucose reduced or increased accordingly. [0155]
  • 2. Suppositories [0156]
  • Composition: [0157]
    Active substance according to the 100 parts by weight
    invention
    Powdered lactose 45 parts by weight
    Cocoa butter 1555 parts by weight
  • The ingredients are processed in the usual way to form suppositories weighing 1.7 g. [0158]
  • 3. Powder for Inhalation [0159]
  • Micronised powdered active substance (compound of formula I; particle size about 0.5 to 7 μm) is packed into hard gelatine capsules in a quantity of 5 mg, optionally with the addition of micronised lactose. The powder is inhaled from conventional inhalers, e.g. according to DE-A 33 45 722, to which reference is hereby made. [0160]
  • The compounds according to the invention can be prepared starting from compounds known from the prior art, using the processes described in the following Examples, inter alia. Other different embodiments of the invention and processes will be apparent to anyone skilled in the art from the present specification. However, it is expressly pointed out that these Examples and the associated specification are intended solely for purposes of explanation and should not be regarded as restricting the invention. Reference is further made to German Patent Application P 196 21 038.0 for additional information. [0161]
    • Example 1
  • Preparation of 1-(undecylideneamino)guanidine [C11AG][0162]
  • 1 mol (170.3 g) of undecanol, 1.1 mol (150 g) of aminoguanidine hydrogen carbonate and 1 g of p-toluenesulphonic acid are mixed with 500 ml of toluene and refluxed with stirring. As soon as 2 mol of water have been separated using the water separator, the mixture is allowed to cool, concentrated by rotary evaporation and the dark red oil is taken up in 250 ml of [0163] petroleum ether 40/600. The precipitate formed is suction filtered and washed again with petroleum ether. For recrystallisation the precipitate is dissolved in ethyl acetate and mixed with petroleum ether at boiling temperature (boiling range 40 to 60° C.) until beginning to turn cloudy. Fine crystals are obtained, m.p. 101° C. The structure and purity of the compound were confirmed by analytical and spectroscopic data.
  • The other compounds mentioned in Example 3 are prepared analogously. [0164]
    • Example 2
  • Preparation of 1-(undecylamino) guanidine [H[0165] 2C11AG]
  • 1.2 g of 1-(undecylideneamino)guanidine are placed in an autoclave and hydrogenated over a period of 12 hours in the presence of 0.1 g of 10% palladium on activated charcoal as hydrogenation catalyst in 20 ml of 100% acetic acid under a hydrogen pressure of 60 bar at ambient temperature. Then the catalyst is filtered off and the colourless solution is evaporated to dryness in vacuo. [0166]
  • In this way the title compound is isolated, after recrystallisation from ethyl acetate, in the form of colourless crystals melting in the range from 70-72° C. in quantitative yield. [0167]
    • Example 3
  • The virostatic properties were determined by in vitro tests. The following virus strains were used: [0168]
  • herpes virus [0169]
  • vesicular stomatitis virus [0170]
  • [0171] BVI 1
  • Cell cultures (monkey kidney cells or human fibroblasts) are infected with herpes and a series of cultures are exposed to medium containing various concentrations of the test substance. After 24 hours the concentration of the virus descendants in the cell culture supernatant is determined by plaque assays. The concentration of substance at which the virus replication is inhibited by 50% (IC[0172] 50) is determined from dosage/activity curves.
  • The results obtained from some substances by way of example are listed in the following Table. [0173]
    Substance IC50 μM
    1-(octylidene-amino)guanidine 49.7
    1-(nonylidene-amino)guanidine 29.0
    1-(decylidene-amino)guanidine 28.9
    1-(undecylidene-amino)guanidine 6.8
    1-(dodecylideneamino)guanidine 3.2
    1-(anthracen-9-ylmethylene-amino)guanidine 1.5
    1-(indol-3-ylmethylene-amino)guanidine 19.8
    1-(phenalen-1-ylidene-amino)guanidine 45.4
    • Example 4
  • Protection from endotoxic shock by C11AG is illustrated by FIG. 1: [0174]
  • Mice (strain NMRI/Nu, 8 weeks old, female) were each given 0.2 mg of endotoxin from [0175] E. coli (Sigma, Munich) by intraperitoneal route. The 10 control animals, who had been given 0.2 ml of 5% glucose subcutaneously, died within 24 hours. Nine animals were injected subcutaneously with 50 mg/kg of C11AG 30 minutes before the endotoxin treatment. Of this group, only 2 animals died.
    • Example 5
  • Inhibition of collagen-induced arthritis in the mouse. [0176]
  • An autoimmune reaction against cartilagenous tissue was produced by injecting collagen into DBA/I mice as described (Holmdahl, R. et al., Immunology, 65, 305-310, 1988). Groups of 10 animals were used as control or were given 50 mg/kg or 100 mg/kg of C11AG per day by oral route. The drug was administered in the food (Altromin, powdered food) and the dosage was calculated from the daily food intake. The symptoms were evaluated daily for each individual paw from 0.5-3 as described [R. Holmdahl, et al., Immunology, 65, 305-310, (1988)]. The total symptoms of every animal in each group—on day 7 after the booster injection—are shown in the following Table: [0177]
    Treatment Total Symptoms
    Control 0
    Collagen 35
    Collagen/50 mg/kg C11AG 4.5
    Collagen/100 mg/kg C11AG 1
  • 20 days after the booster injection the animals were killed and the joints were examined by histopathology resulting in the following picture: [0178]
  • In all the untreated animals, inflammatory processes were found, but in the animals and controls treated with 50 and 100 mg/kg of C11AG, no such inflammatory processes could be detected. [0179]
  • The results obtained seven days after the booster injection are graphically shown in FIG. 2. [0180]
    • Example 6
  • [0181]
    Inhibition of neutral SMase
    Compound Neutral SMase IC50 [μM]
    Octylidene-aminoguanidine 63
    Decylidene-aminoguanidine 44
    Undecylidene-aminoguanidine 8.2
    Dodecylidene-aminoguanidine 5.8
    Anthracen-9-ylmethylene-aminoguanidine 1.9
    Indol-3-ylmethylene-aminoguanidine 5
    Phenalen-1-ylidene-aminoguanidine 54
  • [0182] 14C sphingomyelin (10 μg/ml) was incubated with neutral SMase (membrane fraction isolated from mice brains, 10 μg of protein/mixture [according to S. Gatt, Biochem. Biophys. Res. Commun. 68, 235-241 (1976)] in the presence of various concentrations of the test substances (for 2 hours at 37° C. 20 mM Tris, 1 mM MgCl2.pH 7.5). Then the samples were extracted with 5 times the volume of chloroform/methanol (1:1) and the content of radioactive phosphorylcholine in the aqueous phase was determined. The IC50 was obtained from dosage/activity curves.
    • Example 7
  • Inhibition of NO-aynthase induction by C11AG in macrophages. [0183]
  • RAW cells (mouse macrophage line, origin: American Type Culture Collection) were treated with 10 ng/ml of endotoxin from [0184] E. coli (LPS) in the presence of different concentrations of C11AG. After 16 hours the nitrite content in the culture medium was measured using the method described [K. Tschaikowsky, M. Meisner, F. Schonhuber and E. Rugheimer, Br. J. Pharmacol. 113 (3): 664-8 (1994)].
  • Measured Values: [0185]
    C11AG concentration [μg/ml] OD 540 nm
    0 0.122
    0.5 0.091
    1 0.075
    2 0.054
    3 0.05
    4 0.038
  • The inhibition of NO-synthase induction is graphically shown in FIG. 3; the NO[0186] 2 concentration [OD measured at 540 nm] is plotted against the C11AG concentration [μg/ml] for 10 ng/ml of LPS.
    • Example 8
  • C11AG-IC[0187] 50 determination of acidic and neutral Smase.
  • [0188] 14C sphingomyelin (10 μg/ml) were incubated with neutral SMase (membrane fraction isolated from mouse brains, 10 μg protein/mixture, according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976) or with acidic SMase (microsome fraction from macrophage 5 μg of protein/mixture isolated according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976) in the presence of various concentrations of the test substances, for 2 hours at 37° C. in 20 mM Tris, 1 mM MgCl21 pH 7.5 (neutral SMase) or in 50 mM sodium acetate, 1 mM MgCl2, pH 5.6 (acid SMase). Then the samples were extracted with 5 times the volume of chloroform/methanol (1:1) and the content of radioactive phosphorylcholine in the aqueous phase was determined. The release of phosphorylcholine in the untreated mixtures corresponds to 100% enzyme activity.
  • Measured Values: [0189]
    C11AG concentration nSMase activity aSMase activity
    [μg/ml] [%] [%]
    0 100 100
    1 61 101
    10 18 102
    100 0 31
  • FIG. 4 shows, by a simple logarithmic representation, the sphingomyelinase inhibition for neutral and acidic sphingomyelinase [in %] as a function of the C11AG concentration [μg/ml]. [0190]
    • Example 9
  • Inhibition of the growth of papillomas. [0191]
  • [0192] Mastomys natalensis with papillomas triggered by a papilloma virus [see E. Amtmann and K. Wayss:
    Figure US20010023251A1-20010920-P00900
    The Mastomys natalensis papilloma virus, in: P. Salzman and P. Howley (Eds.): The Papovaviridae, Vol. 2. Plenum Publishing Corporation (1987)] were given food containing various amounts of C11AG. The food consumption was measured and from this the daily oral dose of C11AG was calculated. The size of the papilloma was measured in two dimensions by means of a sliding gauge and the relative growth was calculated. 10 animals were treated per dose.
  • FIG. 5 graphically shows the average tumour size as a function of the duration of treatment for various doses of C11AG. Curve A shows the tumour growth of the control animals. Curve B shows the pattern of size for a dosage of 50 mg/kg C11AG and curve C shows the corresponding pattern for 100 mg/kg C11AG. [0193]
    • Example 10
  • Hydrogenated C11AG-IC[0194] 50: Measurement of acidic and neutral Smase.
  • [0195] 14C-sphingomyelin (10 μg/ml) was incubated with neutral SMase (membrane fraction from mouse brain, 10 μg of protein/batch, isolated according to Gatt, S. Biochem. Biophys. Res. Commun. 68, 235-241, 1976) or with acid SMase (microsome fraction from macrophages 5 μg of protein per batch [isolated according to S. Gatt, Biochem. Biophys. Res. Commun. 68, 235-241, (1976)] in the presence of various concentrations of the test substances for 2 hours at 37° C. in 20 mM Tris, 1 mM MgCl2, pH 7.5 (neutral SMase) or in 50 mM sodium acetate, 1 mM MgCl2, pH 5.6 (acidic SMase). Then the samples were extracted with 5 times the volume of chloroform/methanol (1:1) and the content of radioactive phosphorylcholine in the aqueous phase was determined. The release of phosphorylcholine in the untreated batches corresponds to 100%.
  • Measured Values: [0196]
    H2C11AG concentration nSMase activity aSMase activity
    [μg/ml] [%] [%]
    0 100 100
    1 73 100
    10 22 97
    100 2 32
  • FIG. 6 shows, by a simple logarithmic representation, the sphingomyelinase inhibition for neutral—curve A—and acidic sphingomyelinase [in %]—curve B—as a function of the H[0197] 2C11AG concentration [μg/ml].
    • Example 11
  • Prevention of lethal endotoxic shock in the mouse by H[0198] 2C11AG.
  • 10 mice of the Balb C strain (about 8 weeks old) were given 0.7 mg of endotoxin from [0199] E. coli (in 0.2 ml of isotonic saline solution) by intraperitoneal injection. 10 animals were given 100 mg/kg of H2C11AG (dissolved in twice distilled water) by oesphageal tube 2 hours before the LPS treatment. The control animals were given water. The surviving animals were observed for 12 days.
  • Results: control: 2 survivors (20%), 100 mg/kg H[0200] 2C11AG (hydrogenated C11AG): 9 survivors (90%).
  • FIG. 7 shows the survival rate of untreated experimental animals (A) compared with those who were treated with a dose of 100 mg H[0201] 2C11AG, as described above.
  • To illustrate the nomenclature used in the application, here are the structures of some of the compounds mentioned: [0202]
  • 1-(Anthracen-9-ylmethylene-amino)guanidine [0203]
    Figure US20010023251A1-20010920-C00004
  • 1-(Indol-3-ylmethylene-amino)guanidine [0204]
    Figure US20010023251A1-20010920-C00005
  • 1-(Phenalen-1-ylidene-amino)guanidine [0205]
    Figure US20010023251A1-20010920-C00006

Claims (17)

1. Compounds of general formula I:
Figure US20010023251A1-20010920-C00007
wherein
X denotes R1, —NHR1, —NH—NH—CHR1R2, —NH—N═CR1R2,
Figure US20010023251A1-20010920-C00008
R1 and R2 independently of each other denote hydrogen, a straight-chained or branched C3-20-alkyl, C3-20-cycloalkyl group, an adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, indolyl, quinolyl, anthracenyl, phenanthryl, perinaphthyl or quinuclidinyl group, whilst the above-mentioned straight-chained or branched C3-20-alkyl group may be substituted by a hydroxy, C1-4-alkoxy group, a halogen atom or an amino group and the above-mentioned C3-20-cycloalkyl group may be substituted by a hydroxy, C1-4-alkoxy, C1-4-alkyl group or by a halogen atom or an amino group, and wherein, if X denotes —NH—N═CR1R2, only one of the substituents R1 and R2 can represent hydrogen,
optionally in the form of the individual optical isomers, mixtures of the individual isomers or racemates, tautomers such as geometrical isomers e.g. cis/trans isomers, as well as in the form of the free bases or corresponding acid addition salts with pharmacologically acceptable acids.
2. Compounds of general formula I according to
claim 1
, characterised in that
X denotes —NH—NH—CH2R1 and —NH—N═CHR1
R1 denotes C8-20-alkyl, either branched or unbranched.
3. Compounds of general formula I according to
claim 1
, characterised in that
X denotes —NH—NH—CH2R1 and —NH—N═CHR1, and
R1 denotes an unbranched decyl group.
4. Pharmaceutical preparation, characterised in that it contains a compound according to
claim 1
 and the acid addition salts thereof with pharmaceutically acceptable acids together with conventional excipients and carriers.
5. Pharmaceutical preparation according to
claim 4
, characterised in that it contains a compound according to
claim 2
 and the acid addition salts thereof with pharmacologically acceptable acids together with conventional excipients and carriers.
6. Pharmaceutical preparation according to
claim 4
, characterised in that it contains a compound according to
claim 3
 and the acid addition salts thereof with pharmacologically acceptable acids together with conventional excipients and carriers.
7. Use of compounds according to one of
claims 1
 to
3
 for preparing a drug for inhibiting sphingomyelinase.
8. Use of compounds according to
claim 7
 for preparing a drug for inhibiting neutral sphingomyelinase.
9. Use of compounds according to one of claims 7 and 8 for preparing a drug for the treatment of inflammatory diseases and autoimmune diseases.
10. Use of compounds according to
claim 9
 for preparing a drug for treating rheumatoid arthritis, seronegative arthropathy, emphysema bronchitis, chronic obstructive pulmonary disease(COPD), osteoarthrits, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis, iridocyclitis, uveitis, optic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/Wegner's granulomatosis, sarcoidosis and orchitis/vasectomy reversal procedures.
11. Use of compounds according to one of claims 7 and 8 for preparing a drug for the treatment of cardiovascular diseases.
12. Use of compounds according to
claim 11
 for preparing a drug for the treatment of cardiac stun syndrome, myocardial infarction, congestive heart failure and arteriosclerosis.
13. Use of compounds according to one of claims 7 and 8 for preparing a drug for treating infectious diseases.
14. Use of compounds according to
claim 13
 for preparing a drug for the treatment of papilloma virus infections, herpes virus infections, HIV infection/HIV neuropathology, meningitis, hepatitis, septic arthritis, peritonitis, pneumonia, bronchitis, epiglottitis, E. coli 0157:H7 infection, haemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, malaria, Dengue haemorrhagic fever, leishmaniasis, leprosy, toxic shock syndrome, Streptococcal myositis, gas gangrene, mycobacterium tuberculosis infections, mycobacterium avium intracellular infections, pneumocystosis, pelvic inflammatory disease, orchitis/epidydimitis, legionella, lyme disease, influenza A virus infections, infections caused by Epstein-Barr virus, viral associated haemaphagocytic syndrome, viral encephalitis/aseptic meningitis.
15. Use of compounds according to one of claims 7 and 8 for preparing a drug for treating malignant diseases and for tumour therapy.
16. Use of compounds according to
claim 15
 for preparing a drug for tumour therapy in conjunction with chemotherapy, radiotherapy and cytokine treatment, such as, for example: TNF-α treatment, for treating sarcomas, carcinomas, leukaemias
ALL
AML
CML
CLL
small cell and non-small cell bronchial carcinoma
breast cancer
squamous cell carcinoma
Hodgkin's disease, non-Hodgkin's lymphoma
multiple melanoma
Kaposi's sarcoma
colorectal carcinoma
nasopharyngeal carcinoma
malignant histiocytosis
paraneoplastic syndrome/hypercalcaemia of malignancy.
17. Process for preparing compounds according to
claim 2
, characterised in that an aldehyde or a ketone of general formula R1CHO or R1C(O)R2, wherein R1 and/or R2 have the meanings given in
claim 2
, is reacted with an aminoguanidine and optionally the imine function resulting from this reaction is reduced by methods known per se in the presence of a hydrogenation catalyst under elevated hydrogen pressure, the reaction product is isolated and the corresponding acid addition salt is optionally formed with a pharmacologically acceptable acid.
US09/815,995 1996-05-24 2001-03-23 Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions Expired - Fee Related US6444706B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/815,995 US6444706B2 (en) 1996-05-24 2001-03-23 Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19621038.0 1996-05-24
DE19621038A DE19621038A1 (en) 1996-05-24 1996-05-24 Aminoguanidines, processes for their preparation and medicaments containing these compounds
DE19621038 1996-05-24
US09/194,321 US6284798B1 (en) 1996-05-24 1997-05-23 Guanidine derivatives, methods of preparing them and their use as drugs
US09/815,995 US6444706B2 (en) 1996-05-24 2001-03-23 Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/194,321 Division US6284798B1 (en) 1996-05-24 1997-05-23 Guanidine derivatives, methods of preparing them and their use as drugs
PCT/EP1997/002658 Division WO1997045401A1 (en) 1996-05-24 1997-05-23 New guanidine derivatives, methods of preparing them and their use as drugs

Publications (2)

Publication Number Publication Date
US20010023251A1 true US20010023251A1 (en) 2001-09-20
US6444706B2 US6444706B2 (en) 2002-09-03

Family

ID=7795277

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/194,321 Expired - Fee Related US6284798B1 (en) 1996-05-24 1997-05-23 Guanidine derivatives, methods of preparing them and their use as drugs
US09/815,995 Expired - Fee Related US6444706B2 (en) 1996-05-24 2001-03-23 Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions
US09/815,992 Abandoned US20010025055A1 (en) 1996-05-24 2001-03-23 New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/194,321 Expired - Fee Related US6284798B1 (en) 1996-05-24 1997-05-23 Guanidine derivatives, methods of preparing them and their use as drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/815,992 Abandoned US20010025055A1 (en) 1996-05-24 2001-03-23 New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Country Status (11)

Country Link
US (3) US6284798B1 (en)
EP (1) EP0918750B1 (en)
AR (1) AR007286A1 (en)
AT (1) ATE222236T1 (en)
AU (1) AU734871B2 (en)
CA (1) CA2259033C (en)
DE (2) DE19621038A1 (en)
ES (1) ES2183180T3 (en)
NZ (1) NZ333520A (en)
WO (1) WO1997045401A1 (en)
ZA (1) ZA974574B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018029618A1 (en) 2016-08-11 2018-02-15 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Antibacterial guanidine derivatives

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005326D0 (en) * 2000-03-06 2000-04-26 Deutsches Krebsforsch Enzymes and uses relating thereto
CA2432978C (en) 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE10149919A1 (en) * 2001-10-10 2003-04-24 Biosphings Ag New carboxylic acid salts of guanidine derivatives useful as sphingomyelinase inhibitors for treating e.g. tumor, cardiovascular or viral diseases
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2585775C (en) * 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
WO2006050265A2 (en) * 2004-10-29 2006-05-11 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
JP5732182B2 (en) * 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． Compositions and methods for treating eye diseases and symptoms
PL2087002T3 (en) * 2006-10-27 2015-02-27 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate
FI119513B (en) 2007-03-07 2008-12-15 Dextech Medical Ab Modified hydroxy polymer conjugates having lethal effect on tumor cells
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
BRPI0822415B8 (en) * 2008-04-07 2021-05-25 Dextech Medical Ab modified hydroxypolymer conjugate, use of modified hydroxypolymer conjugate, composition having tumor cell killing effect, and method for producing the modified hydroxypolymer conjugate
WO2010048164A2 (en) * 2008-10-20 2010-04-29 University Of South Florida N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010054223A1 (en) 2008-11-06 2010-05-14 Musc Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
AU2009332952A1 (en) * 2008-12-30 2011-07-21 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
TW202126649A (en) 2019-09-26 2021-07-16 瑞士商諾華公司 Antiviral pyrazolopyridinone compounds
EP4217001A4 (en) * 2020-09-22 2024-04-24 Rythera Therapeutics, Inc. Composition and method for prevention and treatment of cutaneous radiation injury
CN118141793A (en) * 2022-05-17 2024-06-07 中国医学科学院基础医学研究所 Use of metformin and other guanidine-containing compounds to solubilize summer-lyone crystals and to alleviate inflammation in acute lung injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB932951A (en) * 1959-02-02 1963-07-31 May & Baker Ltd Improvements in or relating to guanidines
US3914308A (en) 1969-11-20 1975-10-21 Texaco Inc Solubilizing process
JPS5815913A (en) * 1981-07-21 1983-01-29 Mitsubishi Chem Ind Ltd Cardiac agent
US5093525A (en) 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4709094A (en) 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
WO1990002398A1 (en) 1988-08-18 1990-03-08 Kabushiki Kaisha Sankyo Seiki Seisakusho Magnetic head
DE3924129A1 (en) 1989-07-20 1991-01-31 Bosch Gmbh Robert MONITORING DEVICE FOR AN IGNITION STAGE ON AN INTERNAL COMBUSTION ENGINE
US5002365A (en) 1989-10-16 1991-03-26 Eastman Kodak Company Beam splitter for color imaging apparatus
ATE182624T1 (en) 1990-07-11 1999-08-15 Univ New York PHOSPHOTYROSINE PHOSPHATASE AS A NEW RECEPTOR TYPE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018029618A1 (en) 2016-08-11 2018-02-15 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Antibacterial guanidine derivatives

Also Published As

Publication number Publication date
NZ333520A (en) 2000-10-27
DE59707976D1 (en) 2002-09-19
CA2259033A1 (en) 1997-12-04
EP0918750A1 (en) 1999-06-02
ZA974574B (en) 1998-03-03
WO1997045401A1 (en) 1997-12-04
AU3028897A (en) 1998-01-05
US6444706B2 (en) 2002-09-03
ES2183180T3 (en) 2003-03-16
AU734871B2 (en) 2001-06-21
US6284798B1 (en) 2001-09-04
ATE222236T1 (en) 2002-08-15
CA2259033C (en) 2011-07-05
US20010025055A1 (en) 2001-09-27
DE19621038A1 (en) 1997-11-27
AR007286A1 (en) 1999-10-27
EP0918750B1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
US6284798B1 (en) Guanidine derivatives, methods of preparing them and their use as drugs
DE69233401T2 (en) BRAZED CYCLIC POLYAMINES WITH ANTI-HIV EFFECT
KR910000854B1 (en) Process for the preparation of aromatic biocidal compounds
AU668107B2 (en) Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5525598A (en) Gallium (III) complexes in pharmaceutical compositions
DE2607620A1 (en) OLEFINE DERIVATIVES OF AMINO ACIDS AND THE PROCESS FOR THEIR PRODUCTION
CA2007117A1 (en) Beta-adrenergic agonists
US5541160A (en) Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US4444776A (en) Dipyrido (4,3-B) (3,4-F) indoles, process for obtaining them, therapeutical use and pharmaceutical compositions
AT394725B (en) Process for the preparation of novel mitomycin-C analogues
EP0537575A1 (en) Hydrobromide of DC-89 derivative having antitumor activity
AU592559B2 (en) 5-Pyrimidinecarboxamides and treatment of leukemia and tumors therewith
EP3763728A1 (en) Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method therefor and application thereof
WO2024020409A1 (en) Therapeutic compounds, formulations, and use thereof
JPH0551597B2 (en)
US4806568A (en) Gossypol derivatives
EP0975592B1 (en) Benzyloxy prodigiosine compounds
US20100113505A1 (en) Amino-naphthyridine derivatives
DE3043437C2 (en)
RU2768451C1 (en) Selective receptor antagonist type a2a
EP0548345A1 (en) Pharmaceutical compositions
DE69011235T2 (en) Derivatives of N- (vincristinyl-23) and N- (noranhydro-5-vinblastinyl-23) of amino-1-methylphosphonic acid, their methods of preparation and pharmaceutical compositions containing them.
US4423073A (en) Fluorinated diaminopentene derivatives
DE3883434T2 (en) Mitomycin analogs, processes for their preparation and pharmaceutical preparations.
EP0015673B1 (en) 3-amino-4-homoisotwistane derivatives for use as antiviral agents, process for their preparation and compositions containing them

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOSPHINGS AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CANCER RESEARCH VENTURES LIMITED;REEL/FRAME:017097/0438

Effective date: 20040220

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140903